Jazz Pharmaceuticals plc (JAZZ)
Market Cap | 7.51B |
Revenue (ttm) | 3.83B |
Net Income (ttm) | 414.83M |
Shares Out | 62.35M |
EPS (ttm) | 6.10 |
PE Ratio | 19.76 |
Forward PE | 6.23 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 67,781 |
Open | 120.51 |
Previous Close | 120.51 |
Day's Range | 120.03 - 121.11 |
52-Week Range | 111.25 - 147.98 |
Beta | 0.59 |
Analysts | Buy |
Price Target | 192.00 (+59.27%) |
Earnings Date | May 8, 2024 |
About JAZZ
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for JAZZ stock is "Buy." The 12-month stock price forecast is $192.0, which is an increase of 59.27% from the latest price.
News
Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024
DUBLIN , March 12, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a virtual R&D Day, Tuesday, March 19, from 8:00 a.m. to 10:00 a.m.
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance
– Total revenues of $3.8 billion in 2023 and $1 billion in 4Q23 –– 27% year-over-year revenue increase from combined key growth drivers: Xywav®, Epidiolex® and Rylaze® –– Oncology revenue surpassed $1...
Jazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors
Mr. Kennedy brings wealth of experience managing high growth organizations focused on creating value for shareholders DUBLIN , Feb. 27, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) tod...
Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer
Mr. Johnson Brings Over 35 Years of Financial and Operating Experience to Leadership Team DUBLIN , Feb. 21, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today...
Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences
DUBLIN , Feb. 20, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences: TD Cowen's 44th Annual He...
Jazz Pharmaceuticals to Report 2023 Full Year and Fourth Quarter Financial Results on February 28, 2024
DUBLIN , Feb. 14, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 full year and fourth quarter financial results on Wednesday, February 28, 20...
Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program
Redx to receive $10 million upfront; potential for up to $870 million in development, regulatory and sales milestone payments in addition to royalties on future net sales Preclinical program expands J...
20 midcap stocks with 2024 upside ranging up to 62%, according to analysts
When investors think about whether to increase their exposure beyond the big companies that grab most of the headlines in the financial media, they are likely to look at small-cap stocks first. After ...
Jazz Pharmaceuticals' PTSD drug fails in mid-stage trial
Jazz Pharmaceuticals said on Thursday its post-traumatic stress disorder (PTSD) drug failed to meet the main goal in a mid-stage study.
Jazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress Disorder
DUBLIN , Dec. 21, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 2 trial (NCT05178316) evaluating JZP150, an investigational small molecul...
Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
DUBLIN , Dec. 20, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 42nd Annual J.P. Morgan Healthcare Confer...
Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer
First presentation of progression-free survival (PFS) primary endpoint data show zanidatamab plus palbociclib and fulvestrant demonstrated a PFS of 67% at 6 months and a median PFS of 12 months in pat...
Jazz Pharmaceuticals to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Society Annual Meeting
Data from nine abstracts to be presented, including real-world outcomes of Epidiolex® (cannabidiol) in treatment-resistant focal epilepsies Presentations include data on U.S. caregiver-reported seizur...
Jazz Pharmaceuticals to Present New Data Highlighting Advancements in Solid Tumors and Rare Blood Cancers at Upcoming Oncology Meetings
New trial results of investigational bispecific antibody zanidatamab presented at SABCS in HER2+/HR+ metastatic breast cancer Strong presence at ASH includes 11 presentations spanning Jazz's portfoli...
Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders
STEVENAGE, England--(BUSINESS WIRE)--Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for rare CNS disorders and other serious brain d...
Jazz Pharmaceuticals Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
– 3Q23 total revenues of $972 million –– Combined revenues from key growth drivers, Xywav®, Epidiolex® and Rylaze®, increased 24% year-over-year –– Raising total and Oncology revenue guidance at the m...
Jazz Pharmaceuticals and MD Anderson Announce Five-Year Collaboration to Evaluate Zanidatamab in HER2-Expressing Cancers
DUBLIN and HOUSTON, Nov. 7, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and The University of Texas MD Anderson Cancer Center today announced a five-year strategic research collaborat...
Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences
DUBLIN , Nov. 1, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following upcoming investor conferences: Jefferies London ...
Jazz Pharmaceuticals to Report 2023 Third Quarter Financial Results on November 8, 2023
DUBLIN , Oct. 25, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 third quarter financial results on Wednesday, November 8, 2023, after the cl...
Jazz Pharmaceuticals Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Real-World, Evidence-Based Approaches for Individualized Treatment in Adults with Narcolepsy at World Sleep 2023
Two presentations focus on cardiovascular disease risk among patients with sleep disorders and the impact of sodium intake on cardiometabolic comorbidities, highlighting the need for low-sodium treatm...
Jazz Pharmaceuticals to Present Latest Advancements in Sleep Medicine at World Sleep 2023
Meeting presentations underscore the increased need for awareness around the cardiovascular and cardiometabolic comorbidities and modifiable risk factors associated with sleep disorders Fourteen abstr...
Jazz Pharmaceuticals to Showcase Growing Impact in Solid Tumor Oncology Research at ESMO 2023
Zanidatamab data demonstrate clinical potential of novel bispecific antibody in HER2-targeted biliary tract and gastric cancers Additional presentations, including a lurbinectedin oral presentation in...
Ligand's Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
SAN DIEGO--(BUSINESS WIRE)--Ligand's Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze.
Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
DUBLIN , Sept. 21, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Commission (EC) has granted marketing authorization for Enrylaze® (JZP458; a recombina...
Jazz Pharmaceuticals to Participate in Three Upcoming Investor Conferences
DUBLIN , Sept. 13, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in three upcoming investor conferences.